CAD

CAD compiles verified cancer antigen peptide datasets to support prediction and filtering of neoantigens—peptides arising from tumor-specific mutations that can elicit immune responses without inducing central tolerance—for personalized cancer vaccine development.

Key Features:

• Rapid prediction and filtering: Performs rapid prediction and filtering of neoantigen peptides to enable candidate prioritization.
• Verified dataset integration: Integrates verified datasets of cancer antigen peptides to provide evidence-backed peptide records.
• Peptide compilation and organization: Compiles and organizes comprehensive peptide information and properties relevant to cancer antigens.
• Algorithm refinement support: Facilitates improvement and refinement of existing algorithms for predicting cancer antigens, with emphasis on neoantigens.
• Neoantigen property insights: Provides curated data to investigate neoantigen characteristics, including origin from tumor-specific mutations and immunogenic potential.

Scientific Applications:

• Vaccine candidate prioritization: Prioritization and selection of neoantigens for personalized cancer vaccine development.
• Neoantigen characterization: Investigation of neoantigen properties, including tumor-specific mutation origin and potential to elicit immune responses without central tolerance.
• Algorithm benchmarking and validation: Benchmarking and refinement of antigen-prediction methodologies using verified peptide datasets.
• Preclinical and clinical research support: Supporting preclinical and clinical research in cancer vaccine development by supplying curated, verified peptide datasets.

Methodology:

Integrates verified cancer antigen peptide datasets and compiles organized peptide information to enable rapid prediction and filtering of neoantigen peptides and to support refinement of prediction algorithms.